Miniaturized Bioassay System Expected To Lower Drug Development Costs
By Biotechdaily staff writers
Posted on 26 Dec 2007
A miniaturized bioassay platform that is expected to enable less expensive and more efficient compound screening has become available to drug developers.Posted on 26 Dec 2007
The technology behind the DropArray system was developed by the Institute of Bioengineering and Nanotechnology (Singapore). The instrument exploits a microfluidic method that reduces the amounts of materials and reagents required to conduct a cell-based assay by a factor of 1,000 and reduces the reaction time by a factor of 10. Thus, a sample volume as small as 100 nl may be tested instead of the 50 to 100 µl required by other instruments.
The DropArray system is being marketed by Curiox Biosystems, a company established by the Institute of Bioengineering and Nanotechnology for this purpose.
"Our technology has the potential to accelerate life science, drug discovery, and clinical research,” said Dr Namyong Kim, team leader at the Institute of Bioengineering and Nanotechnology. "Using our technology, companies can benefit from huge savings in time and money spent on research and development and this would have a direct impact on the cost of medication and new drugs for the consumer.”
Related Links:
Institute of Bioengineering and Nanotechnology
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
8-Channel Pipette
SAPPHIRE 20–300 µL
